[Randomized controlled study of very low-dose Ara-C versus low-dose aclarubicin for the treatment of myelodysplastic syndrome].
Shibuya
T
T
Nagafuji
H
H
Mizuno
S
S
Harada
M
M
D015250:Aclarubicin / Q000008:administration & dosage* / Q000494:pharmacology; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000494:pharmacology; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000494:pharmacology; D002454:Cell Differentiation; D003561:Cytarabine / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000473:pathology; D019014:fas Receptor / Q000378:metabolism
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D019014:fas Receptor; D003561:Cytarabine; D015250:Aclarubicin